Itonis Pharmaceuticals Receives NDC Number From FDA to Enable Production and Marketing of Emesyl(R) Product
02 Giugno 2014 - 11:34PM
Marketwired
Itonis Pharmaceuticals Receives NDC Number From FDA to Enable
Production and Marketing of Emesyl(R) Product
LAGUNA HILLS, CA--(Marketwired - Jun 2, 2014) - Itonis, Inc.
(PINKSHEETS: ITNS) is pleased to announce that the U.S. Food &
Drug Administration (FDA) has published final approval of the
Company's National Drug Code (NDC) number (59067-001) for its
Emesyl® over-the-counter homeopathic product for nausea relief.
In addition, the Company recently received a Notice of Allowance
from the U.S. Patent & Trademark Office for its Emesyl®
trademark.
The NDC number and trademark Notice of Allowance has enabled the
Company to enter the final stage of its product packaging design,
and the production of Emesyl® will soon begin with its
manufacturer, Oasis Health Products.
The Company will market Emesyl® to national retailers, including
drugstore retailers, department stores, cruiselines, and other
strategic retail sectors upon receiving its first production batch
from Oasis. Plans are in place to aggressively market Emesyl® for a
significant share of the worldwide over-the-counter pharmaceutical
market revenues.
"Reaching these significant NDC and trademark milestones
required a lot of hard work and patience. We have wasted no time in
prompting our manufacturer to finalize all steps for the first
production run of Emesyl®, bringing us one step closer to market,"
said Dr. Charles H. Hensley, the inventor of Emesyl® and the Zicam®
Cold Remedy.
The more than 700 of over-the-counter (OTC) drugs on the market
today required a prescription 30 years ago, and the shift to
non-prescription OTC medicines has allowed consumers to reduce the
number of doctor visits for minor ailments. The worldwide market
for OTC drugs could exceed $70 billion by 2015, according to a
report by Visiongain, a British research company.
(http://pharma.about.com/od/Over-the-Counter-Medicine/a/The-Over-the-counter-Drug-Industry.htm)
In another development, the Company's research team received its
30 day testing feedback on its Cloud9 Project and the ITNS
management team has decided to terminate the project in the
interest of shareholder value. The Company, however, is moving
forward with plans to expand with new innovative products and
continues to seek additional ventures that will bring value to the
Company and its shareholders.
About Itonis
Pharmaceuticals Itonis Pharmaceuticals, a division of
Itonis, Inc., is headed by Charles Hensley, Ph.D., and its mission
is to create and market over-the-counter and prescription
homeopathic products that better people's lives. Dr. Hensley is a
pioneer in the development and marketing of safe and effective
therapeutic nutraceutical and homeopathic preparations. He was a
founder of the company that launched the Zicam® Cold Remedy, making
the product a household name and forever changing the marketing and
product placement paradigm for homeopathic drugs in the United
States. Dr. Hensley and his team plan to use the same methodologies
to revolutionize the treatment of several other common ailments and
other chronic diseases.
About Itonis,
Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5,
2005 under the name of Kenshou, Inc., which later changed to
Itonis, Inc. on December 2, 2005. Please visit
www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, seasonal
changes, and other risks detailed from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The actual results may differ materially from those contained in
this press release. The Company disclaims any obligation to update
any statements in this press release.
Contact: Itonis, Inc. Email Contact
Grafico Azioni Itonis (PK) (USOTC:ITNS)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Itonis (PK) (USOTC:ITNS)
Storico
Da Mar 2024 a Mar 2025
